Avidity Partners Management LP
- SEC CIK
- 0001791827
- Latest filing
- Aug 14, 2026
RARE holding history
Ultragenyx Pharmaceutical Inc. in every 13F filed by Avidity Partners Management LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
RARE overviewAll 13F holders of RAREFull Q2 2026 holdings
- Shares (Q3 2025)
- 0
- Sold out in Q3 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 16
- Since Q3 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q3 2025 | 0 | $0 | 0.0% | −154,000−100.0% | Sold out | Holders |
| Q2 2025 | 154,000 | $5.60M | 1.1% | −168,100−52.2% | Reduced | Holders |
| Q1 2025 | 322,100 | $11.7M | 2.4% | −29,900−8.5% | Reduced | Holders |
| Q4 2024 | 352,000 | $14.8M | 1.5% | −400,000−53.2% | Reduced | Holders |
| Q3 2024 | 752,000 | $41.8M | 2.1% | −208,000−21.7% | Reduced | Holders |
| Q2 2024 | 960,000 | $39.5M | 1.7% | +26,500+2.8% | Added | Holders |
| Q1 2024 | 933,500 | $43.6M | 1.5% | +89,000+10.5% | Added | Holders |
| Q4 2023 | 844,500 | $40.4M | 1.5% | +300,500+55.2% | Added | Holders |
| Q3 2023 | 544,000 | $19.4M | 0.8% | −356,700−39.6% | Reduced | Holders |
| Q2 2023 | 900,700 | $41.5M | 1.5% | −1,226,200−57.7% | Reduced | Holders |
| Q1 2023 | 2,126,900 | $85.3M | 2.8% | −863,100−28.9% | Reduced | Holders |
| Q4 2022 | 2,990,000 | $138.5M | 3.2% | +938,400+45.7% | Added | Holders |
| Q3 2022 | 2,051,600 | $85.0M | 1.8% | +572,100+38.7% | Added | Holders |
| Q2 2022 | 1,479,500 | $88.3M | 2.0% | +610,500+70.3% | Added | Holders |
| Q1 2022 | 869,000 | $63.1M | 1.4% | +169,000+24.1% | Added | Holders |
| Q4 2021 | 700,000 | $58.9M | 1.2% | +245,000+53.8% | Added | Holders |
| Q3 2021 | 455,000 | $41.0M | 1.0% | +455,000 | New | Holders |